Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
78 hedge funds and large institutions have $109M invested in Adamas Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 33 increasing their positions, 19 reducing their positions, and 27 closing their positions.
74% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 19
23% more call options, than puts
Call options by funds: $542K | Put options by funds: $441K
21% less funds holding
Funds holding: 99 → 78 (-21)
27% less capital invested
Capital invested by funds: $150M → $109M (-$41.2M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
70% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.59M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.53M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.31M |
| 4 |
KA
Kerrisdale Advisers
Miami,
Florida
|
+$923K |
| 5 |
BlackRock
New York
|
+$646K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$11.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.47M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$5.75M |
| 4 |
Millennium Management
New York
|
-$3.98M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.43M |
ADMS Hedge Fund Activity: Q2 2019 in Review
78 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q2 2019, worth a combined $109M — down 27% from $150M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ADMS and 8 opened new positions — a net loss of 19 holders — while 19 trimmed existing stakes and 33 added.
The largest buyer was Ameriprise, adding an estimated $3.59M. The largest seller was Broadfin Capital, cutting an estimated $11.7M.
- 78 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q2 2019, down from 99 in Q1 2019.
- Funds reported $109M of Adamas Pharmaceuticals stock for Q2 2019, down 27% quarter-over-quarter.
- 8 funds opened new Adamas Pharmaceuticals positions in Q2 2019 and 27 closed out, a net change of -19 holders.
- The largest Adamas Pharmaceuticals buyer in Q2 2019 was Ameriprise, an estimated $3.59M added.
- The largest Adamas Pharmaceuticals seller in Q2 2019 was Broadfin Capital, an estimated $11.7M sold.
Based on aggregated 13F filings for Q2 2019.